View Filing Data

33,595

32,482

94,943

87,511

Earnings Per Share, Basic [Abstract]

(386)

^[1]

(6,908)

^[1]

Net income

$ 33,209

$ 32,482

$ 88,035

$ 87,511

$ 0.59

$ 0.77

$ 1.69

$ 2.12

Net income (in dollars per basic share)

(0.01)

0.00

(0.12)

0.00

0.58

0.77

1.57

2.12

Earnings Per Share, Diluted [Abstract]

0.56

0.69

1.59

1.88

Net income (in dollars per diluted share)

(0.01)

0.00

(0.12)

0.00

$ 0.55

$ 0.69

$ 1.47

$ 1.88

Weighted-average ordinary shares used in computing net income per share:

Basic

57,703

42,028

56,198

41,206

Diluted

60,883

47,241

59,846

46,577

[1]	There was no income tax on the loss from discontinued operations.

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net income	$ 33,209	$ 32,482	$ 88,035	$ 87,511
Other comprehensive income (loss):
Foreign currency translation adjustments	14,248	0	13,860	0
Available-for-sale securities:
Net unrealized (loss) gain on available-for-sale securities, net of income taxes	0	(2)	8	(2)
Reclassification adjustments for gains included in earnings, net of income taxes	0	0	23	0
Other comprehensive income (loss)	14,248	(2)	13,891	(2)
Total comprehensive income	$ 47,457	$ 32,480	$ 101,926	$ 87,509

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Net of tax amount of the income statement impact of the reclassification adjustment for unrealized gain (loss) realized upon the sale of available-for-sale securities.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 18, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

The Company and Summary of Significant Accounting Policies

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Operating activities
Net income	$ 88,035	$ 87,511
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	789	268
Amortization of intangible assets	51,014	5,586
Loss on disposal of property and equipment	146	15
Share-based compensation expense	15,151	9,758
Excess tax benefit from share-based compensation	(4,266)	0
Purchase accounting inventory fair value step-up	17,822	0
Change in fair value of contingent consideration	1,100	0
Movement in deferred income taxes	(8,768)	0
Provision for losses on accounts receivable and inventory	2,696	144
Other non-cash transactions	1,771	394
Loss on extinguishment of debt	0	1,097
Changes in assets and liabilities:
Accounts receivable	(17,773)	(9,347)
Inventories	1,715	648
Prepaid expenses and other current assets	(3,843)	(1,051)
Other long-term assets	(2,297)	190
Accounts payable	(2,543)	5,414
Accrued liabilities	12,327	12,262
Deferred revenue	(48)	(989)
Other long-term liabilities	(301)	(82)
Liability under government settlement	(7,320)	(3,881)
Net cash provided by operating activities	145,407	107,937
Investing activities
Acquistions, net of cash acquired	(542,531)	0
Purchases of marketable securities	(37,443)	(12,135)
Proceeds from sale of marketable securities	81,246	0
Proceeds from maturities of marketable securities	31,988	0
Purchases of property and equipment	(4,993)	(523)
Purchase of product rights	(10,750)	(3,375)
Decrease in restricted cash	0	400
Net cash used in investing activities	(482,483)	(15,633)
Financing activities
Net proceeds from issuance of debt	450,916	0
Proceeds from employee stock purchases, exercise of stock options and warrants	20,995	13,468
Payment of employee withholding taxes upon exercise of share-based awards	(25,299)	0
Excess tax benefit from share-based compensation	4,266	0
Repayment of long-term debt	(5,938)	(41,668)
Payments of debt extinguishment costs	0	(333)
Net repayments under revolving credit facility	0	(7,350)
Net cash provided by (used in) financing activities	444,940	(35,883)
Effect of exchange rates on cash and cash equivalents	(147)	0
Net increase in cash and cash equivalents	107,717	56,421
Cash and cash equivalents, at beginning of period	82,076	44,794
Cash and cash equivalents, at end of period	$ 189,793	$ 101,215

The Company and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing products that address unmet medical needs. Our strategy is to continue to create shareholder value by:


•	Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;


•	Acquiring additional marketed products or products close to regulatory approval to leverage our existing expertise and infrastructure; and


•	Pursuing development of a pipeline of specialty product candidates.

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with Jazz Pharmaceuticals, Inc. treated as the acquiring company for accounting purposes. As part of the Azur Merger, a wholly-owned subsidiary of Azur Pharma merged with and into Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals plc. Prior to the Azur Merger, Azur Pharma changed its name to Jazz Pharmaceuticals plc. Upon the consummation of the Azur Merger, the historical financial statements of Jazz Pharmaceuticals, Inc. became our historical financial statements. Accordingly, the historical financial statements of Jazz Pharmaceuticals, Inc. only are included in the comparative prior periods. For additional information regarding the Azur Merger see Note 2.

On June 12, 2012, we completed the acquisition of EUSA Pharma Inc., or EUSA Pharma, which we refer to as the EUSA Acquisition. As part of the EUSA Acquisition, an indirect wholly-owned subsidiary of Jazz Pharmaceuticals plc merged with and into EUSA Pharma, with EUSA Pharma continuing as the surviving corporation and as an indirect wholly-owned subsidiary of Jazz Pharmaceuticals plc. For additional information regarding the EUSA Acquisition see Note 2.

Unless otherwise indicated or the context otherwise requires, references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries, including its predecessor, Jazz Pharmaceuticals, Inc., except that all such references prior to the effective time of the Azur Merger on January 18, 2012 are references to Jazz Pharmaceuticals, Inc. and its consolidated subsidiaries. All references to “Azur Pharma” are references to Jazz Pharmaceuticals plc (f/k/a Azur Pharma Public Limited Company) and its consolidated subsidiaries prior to the effective time of the Azur Merger on January 18, 2012. The disclosures in this report relating to the pre-Azur Merger business of Jazz Pharmaceuticals plc, unless noted as being the business of Azur Pharma prior to the Azur Merger, pertain to the business of Jazz Pharmaceuticals, Inc. prior to the Azur Merger.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the annual consolidated financial statements and accompanying notes of Jazz Pharmaceuticals, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2011 that we filed on behalf of and as successor to Jazz Pharmaceuticals, Inc. Because the Azur Merger was consummated after December 31, 2011, we also filed a separate Annual Report on Form 10-K covering the last full fiscal year of Azur Pharma that includes the annual consolidated financial statements and accompanying notes of Azur Pharma (Commission File Number 333-177528). The results of operations of the acquired Azur Pharma and EUSA Pharma businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, have been included in our condensed consolidated financial statements since the effective dates of the Azur Merger and the EUSA Acquisition, respectively.

In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements of Jazz Pharmaceuticals, Inc. and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for the year ending December 31, 2012, for any other interim period or for any future period.

The consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.

Significant Risks and Uncertainties

Our financial results are significantly influenced by sales of Xyrem, and maintaining and increasing sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions, and continued acceptance of Xyrem as safe and effective by physicians and patients. During 2010, an abbreviated new drug application, or ANDA, was filed with the United States Food and Drug Administration, or FDA, by a third party seeking to market a generic form of Xyrem. We have sued that third party for infringement of our patents, and the litigation is ongoing. If an ANDA for Xyrem is approved and a generic version of Xyrem is introduced, our sales of Xyrem would be adversely affected. In addition, we are continuing our ongoing work on various regulatory matters, including changes to our Risk Evaluation and Mitigation Strategy, or REMS, documents for Xyrem, changes to the Xyrem product label and follow-up with respect to the warning letter we received from the FDA in October 2011 and the Form FDA 483 we received in May 2012. We do not know the terms on which we and the FDA will agree to updates to the Xyrem label or to our updated Xyrem REMS documents, whether the FDA will take further action, or require us to take further action with respect to our adverse event reporting, or whether the FDA will ultimately conclude we have not taken all appropriate corrective actions or require additional data analysis in connection with the warning letter, the Form FDA 483 or other regulatory interactions. The FDA may impose requirements or otherwise take, or require us to take, actions that could make it more difficult or expensive for us to distribute Xyrem, make competition easier and/or negatively affect the commercial success of Xyrem.

In addition to risks related specifically to Xyrem, we are subject to risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the need to successfully integrate and grow our combined business after the EUSA Acquisition and Azur Merger; the need to obtain appropriate pricing and reimbursement for our products in an increasingly challenging environment; the ongoing regulation and oversight by the FDA, the U.S. Drug Enforcement Administration, and similar foreign regulatory agencies; the challenges of achieving and maintaining commercial success of our products; the dependence on key customers and sole source suppliers; dependence on the protection of intellectual property rights; and the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval.

Business Acquisitions

Our condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date, and that the fair value of acquired in-process research and development, or IPR&D, be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings.

Concentrations of Risk

Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents and marketable securities. Our investment policy permits investments in debt securities issued by the U.S. government or its agencies, corporate bonds or commercial paper issued by U.S. corporations, certain money market mutual funds, certain repurchase agreements, and tax-exempt obligations of states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.

We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to hospitals, pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of September 30, 2012, five customers accounted for 76% of gross accounts receivable and one customer, Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, accounted for 50% of gross accounts receivable. As of December 31, 2011, Express Scripts accounted for 79% of gross accounts receivable.

We rely on certain sole suppliers for drug substance and certain sole manufacturing partners for certain of our marketed products and product candidates.

Foreign Currency

Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.

Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded within “Foreign exchange and other” in the accompanying condensed consolidated statements of income.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Net Income per Ordinary Share

Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2012			2011		2012			2011
Numerator:
Income from continuing operations	$	33,595		$	32,482	$	94,943		$	87,511
Loss from discontinued operations	(386		)	—		(6,908		)	—
Net income	$	33,209		$	32,482	$	88,035		$	87,511
Denominator:
Weighted-average ordinary shares - basic	57,703			42,028		56,198			41,206
Dilutive effect of employee equity incentive and purchase plans	1,404			2,632		1,557			2,773
Dilutive effect of warrants	1,776			2,581		2,091			2,598
Weighted-average ordinary shares - diluted	60,883			47,241		59,846			46,577

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.59		$	0.77	$	1.69		$	2.12
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.58		$	0.77	$	1.57		$	2.12
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.56		$	0.69	$	1.59		$	1.88
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.55		$	0.69	$	1.47		$	1.88

Potentially dilutive ordinary shares from employee equity plans and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options, the assumed vesting of outstanding restricted stock units, or RSUs, and the assumed issuance of ordinary shares under our employee stock purchase plan. The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):



	Three Months Ended September 30,		Nine Months Ended September 30,
	2012	2011	2012	2011
Options to purchase ordinary shares and RSUs	1,785	1,335	1,314	1,122

All references to “ordinary shares” in the discussion and table above refer to Jazz Pharmaceuticals, Inc.’s common stock with respect to the comparative prior year periods and to Jazz Pharmaceuticals plc’s ordinary shares with respect to the current year periods. Our earnings per share in the comparative prior year periods were not impacted by the Azur Merger since each share of Jazz Pharmaceuticals, Inc. common stock issued and outstanding immediately prior to the effective time of the Azur Merger was canceled and automatically converted into and became the right to receive one ordinary share upon the consummation of the Azur Merger. This one-for-one conversion ratio is referred to in this report as the Azur exchange ratio.

Business Combinations

9 Months Ended

Sep. 30, 2012

Business Combinations

Merger with Azur Pharma

On January 18, 2012, pursuant to an Agreement and Plan of Merger and Reorganization dated as of September 19, 2011, as amended, a wholly-owned subsidiary of Azur Pharma merged with and into Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals plc. Prior to the Azur Merger, Azur Pharma changed its name to Jazz Pharmaceuticals plc. We believe the Azur Merger resulted in a company with a strengthened management team, a broader commercial organization and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline.

At the effective time of the Azur Merger, each share of the common stock of Jazz Pharmaceuticals, Inc. issued and outstanding immediately prior to the effective time of the Azur Merger was canceled and automatically converted into and became the right to receive one ordinary share of Jazz Pharmaceuticals plc. Further, the stock options and stock awards outstanding under Jazz Pharmaceuticals, Inc.’s equity incentive plans were converted into stock options and stock awards to purchase or receive an equal number of ordinary shares of Jazz Pharmaceuticals plc with substantially the same terms and conditions, including the same per share exercise price, where applicable. In addition, outstanding warrants to purchase Jazz Pharmaceuticals, Inc. common stock were converted into substantially the same warrants to purchase an equal number of ordinary shares of Jazz Pharmaceuticals plc at the same per share exercise price. Our ordinary shares trade on the same exchange, The NASDAQ Global Select Market, and under the same trading symbol, “JAZZ,” as the Jazz Pharmaceuticals, Inc. common stock prior to the Azur Merger. We are deemed to be the successor to Jazz Pharmaceuticals, Inc. pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended, or the Exchange Act.

The Azur Merger was accounted for as a reverse acquisition under the acquisition method of accounting, with Jazz Pharmaceuticals, Inc. treated as the accounting acquirer. Under the acquisition method of accounting, assets and liabilities of Azur Pharma were recorded at their respective estimated fair values as of the date of the Azur Merger and added to those of Jazz Pharmaceuticals, Inc., including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the identifiable net assets. The results of operations of the acquired Azur Pharma business and the estimated fair values of the assets acquired and liabilities assumed have been included in our condensed consolidated financial statements since the date of the Azur Merger.

The total acquisition consideration of $576.5 million was determined based on the market value of our ordinary shares that were held by the historic Azur Pharma shareholders immediately following the closing of the Azur Merger. The closing price of the Jazz Pharmaceuticals, Inc. common stock on January 17, 2012 ($46.64) was used to determine the fair value of consideration because the closing of the transaction on January 18, 2012 occurred prior to the opening of regular trading on January 18, 2012. Immediately following the consummation of the Azur Merger, 12,360,000, or 22%, of our ordinary shares were held by the persons and entities who acquired ordinary shares of Azur Pharma prior to the Azur Merger, and the remaining 43,838,000, or 78%, of the ordinary shares were held by the former stockholders of Jazz Pharmaceuticals, Inc.

During the nine months ended September 30, 2012, we incurred $2.3 million in transaction costs related to the Azur Merger, which primarily consisted of banking, legal, accounting and valuation-related expenses. These expenses were recorded in selling, general and administrative expense in the accompanying condensed consolidated statements of income. During the three and nine months ended September 30, 2012, the contribution of the acquired Azur Pharma business to our total revenues from continuing operations was $17.8 million and $51.8 million, respectively. This does not include revenues of $8.1 million and $19.3 million in the three and nine months ended September 30, 2012, respectively, related to our women's health business which we sold in October 2012. For more details regarding this sale, see Note 14.

The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the closing date of the Azur Merger based upon their respective estimated fair values as summarized below (in thousands):



Cash and cash equivalents	$	81,751
Accounts receivable	12,975
Inventories	15,344
Property and equipment	370
Intangible assets	325,000
Goodwill	201,524
Other assets	4,862
Accounts payable and accrued liabilities	(52,148		)
Purchased product rights liability	(11,899		)
Above market lease obligation	(1,315		)
Total purchase price	$	576,464

Asset categories acquired in the Azur Merger included working capital, long-term assets and liabilities, fixed assets and identifiable intangible assets, including IPR&D. The allocation of the purchase price for the Azur Merger has been prepared on a preliminary basis and we will finalize these amounts as we obtain the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the date of the Azur Merger may result in retrospective adjustments to the amounts recorded. These changes could be significant. We expect to finalize these amounts no later than one year from the date of the Azur Merger. Through September 30, 2012, we have not recorded any measurement period adjustments related to the Azur Merger.

The intangible assets as of the closing date of the Azur Merger included (in thousands):



Acquired developed technologies	$	323,000
In-process research and development	2,000
Total intangible assets	$	325,000

Intangible assets related to acquired developed technologies reflect the estimated fair value of the rights we acquired to those products in the Azur Merger. The fair value was determined using an income approach, which recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated direct costs for each product line. Indications of value are developed by discounting these benefits to their present worth at a discount rate that reflects the current return requirements of the market. Acquired developed technologies are finite-lived intangible assets and are being amortized over their estimated lives ranging from two to 15 years.

The excess of the purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the Azur Merger. We believe the factors that contributed to goodwill include synergies that are specific to our consolidated business and not available to market participants, the acquisition of a talented workforce that expands our expertise in business development and commercializing pharmaceuticals products as well as other intangible assets that do not qualify for separate recognition. We do not expect any portion of this goodwill to be deductible for tax purposes.

Acquisition of EUSA Pharma

On June 12, 2012, pursuant to an Agreement and Plan of Merger dated as of April 26, 2012, or the EUSA Acquisition Agreement, an indirect wholly-owned subsidiary of Jazz Pharmaceuticals plc merged with and into EUSA Pharma, with EUSA Pharma continuing as the surviving corporation and as an indirect wholly-owned subsidiary of Jazz Pharmaceuticals plc. The EUSA Acquisition has contributed to our expanded portfolio of specialty pharmaceutical products and product candidates, including in particular, Erwinaze, as well as given us a strengthened management team and an enhanced commercial platform, adding EUSA Pharma’s specialty commercial infrastructure in the United States and Europe and its international distribution network to our existing U.S. specialty product platform.

The EUSA Acquisition was accounted for using the acquisition method of accounting under which assets and liabilities of EUSA Pharma were recorded at their respective estimated fair values as of the date of the EUSA Acquisition and added to those of Jazz Pharmaceuticals plc including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the identifiable net assets. The results of operations of EUSA Pharma and the estimated fair values of the assets acquired and liabilities assumed have been included in our condensed consolidated financial statements since the date of the EUSA Acquisition.

At the closing of the EUSA Acquisition, we made an upfront cash payment of $678.4 million. Under the EUSA Acquisition Agreement, we also agreed to make an additional contingent payment of $50.0 million in cash if Erwinaze achieves U.S. net sales (as defined in the EUSA Acquisition Agreement) of $124.5 million or greater in 2013. $50.0 million of the amount paid at closing was deposited in an escrow account, to be held for 12 months as partial security for our indemnification rights under the EUSA Acquisition Agreement. In October 2012, we received a working capital adjustment of $2.3 million, decreasing the escrow account balance to $47.7 million. $25.0 million of the potential contingent payment, if payable, would be subject to reduction for indemnification claims, if any, that are not fully satisfied by the funds in the escrow account. The initial estimate of fair value of the contingent consideration was $35.1 million, which was recorded as a non-current liability and included in the total purchase price as summarized below:



Base payment	$	650,000
Cash acquired	54,117
Working capital and other adjustments	(25,719		)
Upfront payment in accordance with agreement	678,398
Estimated fair value of contingent consideration	35,100
Total purchase price	$	713,498

During the nine months ended September 30, 2012, we incurred $9.9 million in transaction costs related to the EUSA Acquisition, which primarily consisted of banking, legal, accounting and valuation-related expenses. These expenses were recorded in selling, general and administrative expense in the accompanying condensed consolidated statements of income.

During the three and nine months ended September 30, 2012, the contribution of the acquired EUSA Pharma business to our total revenues was $42.1 million and $50.0 million, respectively, as measured from the date of the EUSA Acquisition. The portion of total expenses and net income associated with the acquired EUSA Pharma business was not separately identifiable due to the integration with our operations.

The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the closing date of the EUSA Acquisition based upon their respective estimated fair values as summarized below (in thousands):



Cash and cash equivalents	$	54,117
Accounts receivable (1)	23,354
Inventories	36,360
Prepaid assets	6,212
Property and equipment	764
Intangible assets	616,970
Goodwill	206,452
Other assets	436
Accounts payable and accrued liabilities	(44,502		)
Deferred tax liability	(186,591		)
Other liabilities	(74		)
Total purchase price	$	713,498

____________________

(1)

The estimated fair value of trade receivables acquired was $23.4 million. The gross contractual amount of trade receivables was $25.1 million and was recorded net of allowances for wholesaler chargebacks related to government rebate programs, cash discounts for prompt payment and doubtful accounts. We expect that $1.7 million of the gross contractual amount of trade receivables will be uncollectible.

Categories acquired in the EUSA Acquisition included working capital, long-term assets and liabilities, fixed assets and identifiable intangible assets, including IPR&D. The allocation of the purchase price for the EUSA Acquisition has been prepared on a preliminary basis, and we will finalize these amounts as we obtain the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the date of the EUSA Acquisition may result in retrospective adjustments to the amounts recorded. These changes could be significant. We expect to finalize these amounts no later than one year from the date of the EUSA Acquisition. Through September 30, 2012, we had not recorded any measurement period adjustments related to the EUSA Acquisition since the date of acquisition.

The intangible assets as of the closing date of the EUSA Acquisition included (in thousands):



Acquired developed technologies	$	584,470
In-process research and development	32,500
Total intangible assets	$	616,970

Intangible assets related to acquired developed technologies reflect the estimated fair value of the rights we acquired to those products in the EUSA Acquisition. The fair value was determined using an income approach, which recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated direct costs for each product line. Indications of value are developed by discounting these benefits to their present worth at a discount rate that reflects the current return requirements of the market. Acquired developed technologies are finite-lived intangible assets and are being amortized over their estimated lives ranging from two to fourteen years.

The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. We believe the factors that contributed to goodwill include synergies that are specific to our consolidated business and not available to market participants, the acquisition of a talented workforce and a platform for developing and commercializing pharmaceuticals products as well as other intangible assets that do not qualify for separate recognition. We do not expect any portion of this goodwill to be deductible for tax purposes.

Pro forma financial information (unaudited)

The following unaudited supplemental pro forma information presents the combined historical results of operations of Jazz Pharmaceuticals, Inc., Azur Pharma and EUSA Pharma for the three and nine months ended September 30, 2012 and 2011, respectively, as if the Azur Merger and the EUSA Acquisition had each been completed on January 1, 2011. The pro forma financial information includes adjustments to reflect one time charges and amortization of fair value adjustments in the appropriate pro forma periods as though the companies were combined as of the beginning of 2011. These adjustments include:


•	A (decrease)/increase in amortization expense of $(1.3) million and $8.9 million for the three and nine months ended September 30, 2012, respectively, and $15.7 million and $52.4 million, respectively, for the three and nine months ended September 30, 2011 related to the fair value of acquired identifiable intangible assets.


•	The exclusion of transaction-related expenses of $33.1 million for the nine months ended September 30, 2012 and $8.3 million and $8.6 million for the three and nine months ended September 30, 2011, respectively.

•

A decrease in interest expense of $0.7 million and $1.8 million for the three and nine months ended September 30, 2012, respectively, and an increase of $5.1 million and $12.4 million for the three and nine months ended September 30, 2011, respectively, incurred on additional borrowings made to fund the acquisition of EUSA, as if the borrowings had occurred on January 1, 2011, offset by the elimination of actual interest expense incurred by EUSA during the periods presented.

•

The exclusion of other non-recurring expenses of $11.3 million and $58.4 million for the three and nine months ended September 30, 2012, respectively, and the inclusion of $9.4 million and $25.6 million for the three and nine months ended September 30, 2011, respectively, primarily related to the fair value step-up to acquired inventory, share-based compensation incurred from the acceleration of stock option vesting upon closing of the Azur Merger and the EUSA Acquisition, a share-based liability granted to certain former Azur Pharma shareholders and integration-related expenses.

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations (in thousands, except per share data):



	Three Months Ended September 30,				Nine Months Ended September 30,

	2012		2011		2012		2011
Revenues	$	175,515	$	110,571	$	485,222	$	297,613
Net income (loss)	$	46,376	$	332	$	128,744	$	(12,353	)
Net income (loss) per ordinary share - basic	$	0.80	$	0.01	$	2.26	$	(0.23	)
Net income (loss) per ordinary share - diluted	$	0.76	$	0.01	$	2.12	$	(0.23	)

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Inventories

9 Months Ended

Sep. 30, 2012

The components of inventories were as follows (in thousands):



	September 30, 2012		December 31, 2011
Raw materials	$	5,888	$	1,937
Work in process	2,191		524
Finished goods	22,221		1,448
Total inventories	$	30,300	$	3,909

As of September 30, 2012, inventories included $6.1 million related to purchase accounting inventory fair value step-up.

Fair Value

9 Months Ended

Sep. 30, 2012

Fair Value

Cash, cash equivalents and marketable securities consisted of the following (in thousands):



	September 30, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	164,492	$	—	$	—		$	164,492	$	164,492	$	—
Money market funds	25,201		—		—			25,201		25,201		—
Certificates of deposit	100		—		—			100		100		—
Totals	$	189,793	$	—	$	—		$	189,793	$	189,793	$	—


	December 31, 2011
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	33,307	$	—	$	—		$	33,307	$	33,307	$	—
Money market funds	48,518		—		—			48,518		48,518		—
Certificates of deposit	7,300		—		(6		)	7,294		—		7,294
Corporate debt securities	50,371		7		(34		)	50,344		—		50,344
Obligations of U.S. government agencies	18,433		3		(1		)	18,435		251		18,184
Totals	$	157,929	$	10	$	(41	)	$	157,898	$	82,076	$	75,822

Collectively, cash and cash equivalents and marketable securities are considered available-for-sale. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. Proceeds from sales of available-for-sale securities during the nine months ended September 30, 2012 were $81.2 million and were used to partially fund the EUSA Acquisition. Gross realized gains and losses during the three and nine months ended September 30, 2012 were insignificant. All available-for-sale securities held as of September 30, 2012 were cash and cash equivalents.

The following table summarizes, by major security type, our available-for-sale securities and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):



	September 30, 2012								December 31, 2011
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value
Assets:
Available-for-sale securities
Money market funds	$	25,201	$	—	$	—	$	25,201	$	48,518	$	—	$	48,518
Certificates of deposit	—		100		—		100		—		7,294		7,294
Corporate debt securities	—		—		—		—		—		50,344		50,344
Obligations of U.S. government agencies	—		—		—		—		—		18,435		18,435
Total available-for-sale securities at fair value	$	25,201	$	100	$	—	$	25,301	$	48,518	$	76,073	$	124,591
Liabilities:
Contingent consideration	$	—	$	—	$	36,200	$	36,200	$	—	$	—	$	—

As of September 30, 2012, our available-for-sale securities included money market funds and certificates of deposits and their carrying values were approximately equal to their fair values. There were no transfers between the different levels of the fair value hierarchy in 2012.

As of December 31, 2011, our available-for-sale securities included corporate debt securities, obligations of U.S. government agencies and certificates of deposit which were measured at fair value using Level 2 inputs and money market funds which were measured at fair value using Level 1 inputs. We reviewed trading activity and pricing for these investments as of the measurement date. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. As of December 31, 2011, the aggregate fair value of available-for-sale securities which had unrealized losses was $43.6 million.

As part of the EUSA Acquisition, we agreed to make an additional contingent payment of $50.0 million in cash if Erwinaze achieves U.S. net sales of $124.5 million or greater in 2013. The fair value measurement of this contingent consideration obligation is determined using unobservable Level 3 inputs. These inputs include the probability of 2013 U.S. net sales of Erwinaze equaling or exceeding the $124.5 million threshold and the discount rate. A significant increase or decrease in the estimated probability of exceeding the milestone threshold would result in a significantly higher or lower fair value measurement, respectively. The range of the estimated contingent payment is from zero if 2013 U.S. net sales of Erwinaze are less than $124.5 million to $50.0 million if 2013 U.S. net sales of Erwinaze equal or exceed $124.5 million.

The changes in fair value of the contingent consideration payable was estimated as follows (in thousands):



	Level 3
Balance at December 31, 2011	$	—
Amount acquired on June 12, 2012	35,100
Fair value adjustment recorded within selling, general and administrative expenses	1,100
Balance at September 30, 2012	$	36,200

During the period ended September 30, 2012, the change in the fair value reflects the passage of time and not a change in the estimated probability of exceeding the milestone threshold.

As of September 30, 2012, the estimated fair value of our $475.0 million term loan was $477.9 million and the carrying amount was $462.4 million. The fair value was determined using quotes from the administrative agent of our credit facility that are based on bid/ask prices of our term loan (Level 2). For additional information regarding our term loan see Note 7.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Certain Balance Sheet Items

Certain Balance Sheet Items

9 Months Ended

Sep. 30, 2012

Property and equipment consisted of the following (in thousands):



	September 30, 2012			December 31, 2011
Computer software	$	4,191		$	4,010
Computer equipment	3,163			2,046
Furniture and fixtures	1,729			556
Leasehold improvements	3,787			763
Construction-in-progress	1,052			689
Machinery and equipment	93			76
Subtotal	14,015			8,140
Less accumulated depreciation	(7,344		)	(6,583		)
Property and equipment, net	$	6,671		$	1,557

Accrued liabilities consisted of the following (in thousands):



	September 30, 2012		December 31, 2011
Employee compensation and benefits	$	24,761	$	11,643
Rebates and other sales deductions	27,178		12,378
Sales returns reserve	25,596		4,302
Taxes payable	25,449		—
Professional fees	3,217		4,021
Royalties	4,359		267
Other	13,072		2,172
Total accrued liabilities	$	123,632	$	34,783

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2012

Goodwill and Intangible Assets

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



Balance at December 31, 2011	$	38,213
Goodwill arising from the Azur Merger	201,524
Goodwill arising from the EUSA Acquisition	206,452
Goodwill allocated to the divested women's health business (1)	(12,916		)
Foreign exchange	4,379
Balance at September 30, 2012	$	437,652

_________________________


(1)	In September 2012, we entered into a definitive agreement to sell our women's health business. See Note 14 for information regarding discontinued operations and assets held for sale.

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	September 30, 2012								December 31, 2011

	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	12.5	$	920,384	$	(79,265	)	$	841,119	$	49,400	$	(35,634	)	$	13,766
Trademarks	2.3	2,600		(1,985		)	615		2,600		(1,781		)	819
Total finite-lived intangible assets		922,984		(81,250		)	841,734		52,000		(37,415		)	14,585
Acquired IPR&D assets		35,225		—			35,225		—		—			—
Total intangible assets		$	958,209	$	(81,250	)	$	876,959	$	52,000	$	(37,415	)	$	14,585

Based on finite-lived intangible assets recorded as of September 30, 2012, and assuming the underlying assets will not be impaired in the future and that we will not change the expected lives of the assets, future amortization costs were estimated as follows (in thousands):



Year Ending December 31,	Estimated Amortization Expense
2012 (remainder)	$	20,097
2013	77,208
2014	77,014
2015	70,077
2016	66,755
Thereafter	530,583
Total	$	841,734

As of September 30, 2012, intangibles related to the women's health business with a net book value of $41.4 million were classified as assets held for sale. See Note 14 for information regarding discontinued operations and assets held for sale.

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

Commitments and Contingencies

Long-Term Debt

9 Months Ended

Sep. 30, 2012

Long-Term Debt

Term Loan and Revolving Credit Facility

On June 12, 2012, Jazz Pharmaceuticals plc, as guarantor, and Jazz Pharmaceuticals, Inc., as borrower, entered into a $575.0 million credit agreement with Barclays Bank PLC, as administrative agent and certain other lenders. The credit agreement provides for a six-year $475.0 million term loan and a five-year $100.0 million revolving credit facility, which includes a $10.0 million swing line loan sub facility and a $10.0 million letter of credit sub facility. The proceeds from the term loan were used to partially finance the EUSA Acquisition. Borrowings under the term loan bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 4.25% per annum (subject to a 1.0% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 3.25% per annum (subject to a 2.0% prime rate floor). Borrowings under the revolving credit facility bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 4.00% per annum, or the prime lending rate, plus an applicable margin equal to 3.00% per annum, subject to reduction by 0.25% or 0.50% based upon our secured leverage ratio. The revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.50% per annum based upon our secured leverage ratio.

The obligations of Jazz Pharmaceuticals, Inc. under the credit agreement and any hedging or cash management obligations entered into with a lender are guaranteed by Jazz Pharmaceuticals plc and certain of its subsidiaries and are secured by substantially all of their assets.

We may make prepayments of principal without premium or penalty, except that a 1% premium would apply to a repayment via a repricing of the loan under the term loan effected on or prior to June 12, 2013. We are required to make mandatory prepayments of borrowings under the term loan (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), (3) beginning with the fiscal year ending December 31, 2013, 50% of our excess cash flow as defined in the credit agreement (subject to increase to 75% if our secured leverage ratio exceeds 2.25 to 1.0, or decrease to 25% or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.0 or 0.75 to 1.0, respectively), and (4) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions).

Principal repayments of the term loan are due quarterly and are equal to 5% of the original principal amount in the first year, 7.5% in the second year, 10% in each of the third and fourth years and 15% in each of the fifth and sixth years, with any remaining balance payable on the final maturity date. In the three months ended September 30, 2012, $5.9 million of debt principal was repaid.

The credit agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to Jazz Pharmaceuticals plc and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The credit agreement contains a financial covenant that requires Jazz Pharmaceuticals plc and its restricted subsidiaries to maintain a maximum secured leverage ratio. We are currently in compliance with our financial covenants.

The $475.0 million principal amount of the term loan was recorded net of an original issue discount of $7.1 million. We incurred $15.0 million of debt issuance costs associated with the term loan which are recorded under the caption “Other long-term assets” in the accompanying condensed consolidated balance sheets. As of September 30, 2012, the interest rate on the term loan was 5.25%. Interest expense associated with the term loan is recorded using the interest method and includes non-cash interest related to the debt discount and debt issuance costs. The effective interest rate on the term loan is 6.7%. The current portion of the carrying amount of the term loan was $26.7 million as of September 30, 2012.

Financing costs of $3.5 million associated with the revolving credit facility were deferred and are being amortized to interest expense on a straight-line basis over the life of the facility. As of September 30, 2012, we had not borrowed under the revolving credit facility.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Indemnification

In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.

We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we have not recognized any liabilities relating to these obligations as of September 30, 2012 and December 31, 2011. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.

Lease and Other Commitments

We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. Future minimum lease payments under our noncancelable operating leases at September 30, 2012 were as follows (in thousands):



Year Ending December 31,	Lease Payments
2012 (remainder)	$	1,634
2013	6,800
2014	5,830
2015	5,032
2016	4,181
Thereafter	5,839
Total	$	29,316

As a result of the Azur Merger and the EUSA Acquisition, we assumed operating leases that are included in the table above. In the second quarter of 2012, we entered into an operating lease agreement for our new headquarters in Dublin for a term of 10 years, we amended and extended the operating lease for our existing Philadelphia office building for a term of 4 years and we entered into a new operating sublease for additional office space in Palo Alto near our existing office location for a term of 5 years.

As of September 30, 2012, we had $42.0 million of noncancelable purchase commitments due within one year under agreements with contract manufacturers.

Legal Proceedings

We are involved in several legal proceedings, including the following matters:

Xyrem ANDA Matter: On October 18, 2010, we received a Paragraph IV Patent Certification notice, or Paragraph IV Certification, from Roxane Laboratories, Inc., or Roxane, that it filed an abbreviated new drug application, or ANDA, with the United States Food and Drug Administration, or FDA, requesting approval to market a generic version of Xyrem. Roxane’s Paragraph IV Certification alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations”, or Orange Book, on the date of the Paragraph IV Certification are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s Paragraph IV Certification in the United States District Court for the District of New Jersey, or the District Court. We are seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem in violation of our patents. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA will be stayed until the earlier of (i) April 18, 2013, which is 30 months from our October 18, 2010 receipt of Roxane’s Paragraph IV certification notice, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. An additional method of use patent covering the distribution system for Xyrem issued in December 2010 and is listed in the Orange Book, and we amended our lawsuit against Roxane on February 4, 2011 to include the additional patent in the litigation in response to Roxane’s Paragraph IV Certification against this patent, as well as another patent which is not listed in the Orange Book. Another method of use patent covering the distribution system for Xyrem issued in February 2011 and is listed in the Orange Book, and we amended our lawsuit against Roxane on May 2, 2011 to include this additional patent in response to Roxane’s Paragraph IV Certification against it. On April 26, 2012, the District Court held a Markman hearing, a pretrial hearing following which the trial judge construes the claims of a patent, and the District Court issued a Markman order construing the claims in September 2012. A new formulation patent covering Xyrem issued in September 2012 and is listed in the Orange Book. On October 26, 2012, we filed a lawsuit against Roxane in response to Roxane's Paragraph IV Certification against this patent. Our original lawsuit against Roxane has been temporarily stayed while the District Court determines whether to consolidate the lawsuits, and no trial date has been scheduled. We cannot predict the outcome of this matter.

On May 18, 2012, we submitted a Citizen Petition to the FDA addressing the legal and scientific bases for requiring in vivo bioequivalence studies for generic formulations of Xyrem and requesting that the FDA: publish in the Orange Book bioequivalence requirements specifying whether in vitro or in vivo bioequivalence studies, or both, are required for ANDAs referencing Xyrem; not accept for review, review, or approve any ANDA referencing Xyrem unless and until the FDA has published bioequivalence requirements in the Orange Book specifying whether in vitro bioequivalence studies, in vivo bioequivalence studies, or both, are required for such ANDAs; and require in vivo bioequivalence studies for any sodium oxybate drug product for which approval is sought in an ANDA referencing Xyrem to the extent such drug product differs from Xyrem in manufacturing process, pH, excipients, impurities, degradants or contaminants. On October 24, 2012, Roxane submitted comments to this Citizen Petition, arguing that the Citizen Petition should be denied.

On July 10, 2012, we submitted a second Citizen Petition to the FDA addressing the requirements for submission of any ANDA referencing Xyrem. This petition asks the FDA to rescind the acceptance of any previously-accepted ANDA referencing Xyrem, including the Roxane ANDA, that did not contain a proposed risk management system at the time it was accepted for review, because such ANDA would not have demonstrated, as required by law, that the new generic drug product would have the same labeling and conditions of use as Xyrem. This petition further requests that the FDA (i) not accept for review any ANDA referencing Xyrem that does not contain, at the time of its submission, a proposed risk management system sufficient to demonstrate that the new generic drug product has the same labeling and conditions of use as Xyrem; and (ii) determine that if any sponsor, including Roxane, of an ANDA referencing Xyrem that did not contain, at the time it was accepted for review, a proposed risk management system later submits, or resubmits, an ANDA that contains a proposed risk management system sufficient to demonstrate that the new generic drug product would have the same labeling and conditions of use of Xyrem, then such ANDA should not be approved for a period of up to thirty months beginning on the date we receive notice of any Paragraph IV certifications contained in such new ANDA, to the extent that we avail ourselves of our right to initiate a patent infringement action based on such notice. We believe that the FDA’s acceptance of Roxane’s ANDA caused the thirty-month stay under the Hatch-Waxman Act and the related patent litigation between the parties to begin prematurely in a manner contrary to applicable law.

We cannot predict the FDA's response to either of our Citizen Petitions, or the timing thereof, or the effect of any such response on the timing of the potential introduction of a generic version of Xyrem or on the ongoing litigation between us and Roxane.

FazaClo ANDA Matters: Azur Pharma received Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc.; Novel Laboratories, Inc.; and Mylan Pharmaceuticals, Inc., indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo LD. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification in the United States District Court for the District of Delaware. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr Laboratories, Inc., entered into an agreement settling the patent litigation and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD will commence in May 2015 or earlier upon the occurrence of certain events. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. The Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc. matters have been stayed pending reexamination of the patents in the suit. We cannot predict the outcome of the matters with Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc., the reexamination proceedings, or when the stays will be lifted.

Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to either a $10.5 million or $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. On March 14, 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. We submitted a complaint in arbitration alleging that Dr. Cutler’s suit had been improperly filed in Los Angeles and seeking a declaratory judgment that we have complied with all contractual obligations to Dr. Cutler. On July 25, 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside the scope of the arbitration clause in the applicable contract. On November 7, 2012, Azur Pharma and its subsidiary filed challenges to the sufficiency of the complaint in the Superior Court. This matter, like all litigation, carries certain risks, and there can be no assurance of the outcome.

From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

The entire disclosure for commitments and contingencies.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Shareholders' Equity

9 Months Ended

Sep. 30, 2012

Shareholders' Equity

Shareholders’ Equity

Shares and Additional Paid-In Capital

Following the Azur Merger, our capital structure is comprised of ordinary shares and euro deferred shares. The outstanding 4,000,000 non-voting euro deferred shares of €0.01 each are held by nominees and were issued to satisfy the statutory minimum Euro-denominated share capital required for a public limited company incorporated in Ireland. The non-voting euro deferred shares have no right to receive dividends, no rights to attend and vote at our general meetings, are redeemable only at our option and have no substantive right to participate in a distribution of assets upon a winding up of our company. All references to common stock in the comparative prior year reports in the discussion and table below were replaced with references to ordinary shares to reflect the capital structure of Azur Pharma, the legal acquirer in the Azur Merger. Our earnings per share in comparative periods were not impacted by the Azur Merger as a result of the one-for-one Azur exchange ratio.

The total purchase price consideration of $576.5 million related to the Azur Merger was recorded by increasing total par value of our ordinary shares and euro deferred shares by $1,236 and $54,862, respectively; by creating a capital redemption reserve of $0.5 million as required by Irish company law to preserve permanent capital in our company; and by increasing our additional paid-in capital by $575.9 million.

The following table presents a summary of ordinary shares issued and related cash proceeds and payments (in thousands):



	Nine Months Ended September 30, 2012				Nine Months Ended September 30, 2011
	Shares	Cash			Shares	Cash
Azur Merger	12,360	$	—		—	$	—
Employee withholding taxes related to share option exercises (1)	—	(25,299		)	—	—
Employee stock purchase program, vesting of restricted stock units, option and warrant exercises	2,943	20,994			2,184	13,468
Directors deferred compensation plan	45	—			14	—
Totals	15,348	$	(4,305	)	2,198	$	13,468

____________________


(1)	During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees related to the net share settlement of exercised share options in connection with the Azur Merger.

Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss) as at September 30, 2012 and December 31, 2011 were as follows (in thousands):



	Net Unrealized Gains (Losses) On Available-For- Sale Securities			Foreign Currency Translation Adjustments		Total Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2011	$	(31	)	$	—	$	(31	)
Other comprehensive income, net of income taxes	31			13,860		13,891
Balance at September 30, 2012	$	—		$	13,860	$	13,860

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Share-Based Compensation

9 Months Ended

Sep. 30, 2012

Share-Based Compensation

Share-based compensation expense in continuing operations related to share options, restricted stock units, ordinary shares credited to the directors’ phantom share accounts and grants under our employee stock purchase plan was classified as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Selling, general and administrative	$	5,330	$	2,156	$	11,967	$	6,986
Research and development	681		838		1,718		2,342
Cost of product sales	344		201		999		430
Total share-based compensation expense	$	6,355	$	3,195	$	14,684	$	9,758

In addition to the above amounts we recorded share-based compensation expense in discontinued operations related to share options and restricted stock units of $0.3 million and $0.5 million in the three and nine months ended September 30, 2012, respectively.

Share Options

The table below shows (i) the number of shares underlying options to purchase our ordinary shares granted to employees, (ii) the weighted-average grant date fair value per share of those share options, and (iii) certain information about the weighted-average assumptions used in the Black-Scholes option pricing model which was used to estimate the grant date fair value per share:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Shares underlying options granted (in thousands)	1,157			61			2,077			1,312
Weighted-average grant date fair value	$	23.13		$	24.56		$	25.23		$	17.99
Black-Scholes option pricing model assumption information:
Weighted-average volatility	64		%	71		%	64		%	74		%
Weighted-average expected term (years)	4.2			5.6			4.6			5.6
Range of risk-free rates	0.5-0.6%			1.1-2.0%			0.5-1.1%			1.1-2.7%
Expected dividend yield	—		%	—		%	—		%	—		%

Restricted Stock Units

In the nine months ended September 30, 2012, we granted 1.0 million RSUs covering an equal number of our ordinary shares to employees with a weighted-average grant date fair value of $48.98. The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of the RSUs is recognized as expense ratably over the vesting period of 4 years.

As of September 30, 2012, total compensation cost not yet recognized related to unvested share options and RSUs was $80.7 million, which is expected to be recognized over a weighted-average period of 3.3 years.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Related Party Transactions

Related Party Transactions

9 Months Ended

Sep. 30, 2012

In connection with the Azur Merger, we assumed a lease for office space in Dublin, Ireland which expires in October 2029. The lease agreement is with Seamus Mulligan, the former Chief Executive Officer of Azur Pharma, who is currently our Chief Business Officer, International Business Development and a member of our board of directors. Rentals paid on this lease amounted to $0.2 million in the nine months ended September 30, 2012. There were no amounts unpaid at September 30, 2012.

In May 2011, Azur Pharma entered into an agreement with Circ Pharma Limited/Circ Pharma Research and Development Limited, or Circ, companies controlled by Seamus Mulligan, whereby it obtained an option to license certain rights and assets in relation to Tramadol (a chronotherapeutic formulation) and to conduct certain development activities. Azur Pharma paid Circ $250,000 for this option in 2011. Effective July 2012, we terminated the agreement at no cost.

In March 2012, we entered into an underwriting agreement with two underwriters and certain selling shareholders, pursuant to which the selling shareholders agreed to sell to the underwriters 7.9 million of our ordinary shares, resulting in aggregate gross proceeds to the selling shareholders of approximately $390.7 million. The selling shareholders included entities affiliated with certain members of our board of directors, four of our directors and four of our executive officers at the time of the agreement. We did not receive any proceeds from the sale of our ordinary shares by the selling shareholders in the offering, and we agreed to pay expenses of approximately $0.4 million in connection with this offering.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Segment Reporting

9 Months Ended

Sep. 30, 2012

Segment Reporting

We have determined that we operate in one business segment, which is the development and commercialization of specialty pharmaceutical products. The following table presents a summary of total revenues (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Xyrem	$	102,615	$	62,547	$	265,149	$	161,503
Erwinaze/Erwinase	31,652		—		37,660		—
Prialt	5,413		—		20,491		—
Psychiatry:
Luvox CR	11,605		9,669		31,634		24,080
FazaClo LD	6,370		—		17,905		—
FazaClo HD	3,057		—		8,979		—
Other	13,418		—		16,767		—
Product sales, net	174,130		72,216		398,585		185,583
Royalties and contract revenues	1,385		1,077		3,691		3,158
Total revenues	$	175,515	$	73,293	$	402,276	$	188,741

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
United States	$	159,947	$	72,218	$	375,658	$	185,048
Europe	12,164		1,071		21,252		3,362
All other	3,404		4		5,366		331
Total revenues	$	175,515	$	73,293	$	402,276	$	188,741

The following table presents a summary of total revenues from customers that represented more than 10% of our total revenues:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Express Scripts	58	%	85	%	66	%	85	%
Accredo Health Group, Inc.	14	%	—	%	7	%	—	%

The following table presents total long-lived assets by location (in thousands):



	September 30, 2012		December 31, 2011
Ireland	$	191,012	$	—
France	722,877		—
Bermuda	251,887		—
United States	134,263		54,442
Other	41,648		—
Total long-lived assets	$	1,341,687	$	54,442

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Restructuring and Related Activities [Abstract]

Restructuring

9 Months Ended

Sep. 30, 2012

Restructuring

In June 2012, we initiated a restructuring plan to re-align certain support functions across the company following the Azur Merger and the EUSA Acquisition. In connection with this restructuring, we will incur costs of severance for terminated employees as well as retention bonus costs for certain employees retained to assist with the transition process, which is estimated to be completed by the second quarter of 2013. The one-time termination benefits are being recorded over the remaining service period where employees are required to stay through their termination date to receive the benefits. During the three and nine months ended September 30, 2012, we recorded $1.6 million and $2.2 million, respectively, of costs related to these one-time termination benefits, which are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of income. We expect to incur approximately $1 million in additional costs in connection with this plan. There were no restructuring activities during the nine months ended September 30, 2011.

The following table summarizes the amounts related to one-time termination benefits, which are included in the accompanying condensed consolidated statements of income for the nine months ended September 30, 2012 (in thousands):



	Total Termination Benefits
Balance at January 1, 2012	$	—
Costs incurred during the period	2,180
Cash payments	(1,367		)
Balance at September 30, 2012	$	813

The balance for termination benefits at September 30, 2012 is included within accrued liabilities in the accompanying condensed consolidated balance sheet.

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

9 Months Ended

Sep. 30, 2012

Discontinued Operations

On September 5, 2012, we entered into a definitive agreement with Meda Pharmaceuticals Inc. and Meda Pharma, Sàrl, or collectively, Meda, to sell our women's health business for $95.0 million in cash plus an additional amount for certain purchased inventory transferred to Meda upon closing of the sale. The sale was completed in October 2012 (see Note 16). As part of the transaction, Meda purchased the following six products: Elestrin^® (estradiol gel), Gastrocrom^® (cromolyn sodium, USP), Natelle^® One (prenatal vitamin), AVC^™ Cream (sulfanilamide), Gesticare^® DHA (prenatal multi-vitamin) and Urelle^® (urinary antiseptic). In addition, Meda offered positions to approximately 60 of our employees who directly support this business. We decided to sell our women's health business to concentrate our commercial efforts on our core products in our target therapeutic areas. At September 30, 2012, the women's health business met the assets held for sale and discontinued operations criteria. Accordingly, the results of the women's health business are included in income from discontinued operations for the three and nine months ended September 30, 2012. As the women's health business was acquired in the Azur Merger, it is not included in the results for the three and nine months ended September 30, 2011. The net assets associated with the women's health business were reclassified to assets held for sale as of September 30, 2012. Goodwill has been allocated to the divested women's health business using the relative fair value method.

Net revenue and loss from discontinued operations are as follows (in thousands):



	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Product sales, net	$	8,086		$	19,277

Loss from discontinued operations (1)	$	(386	)	$	(6,908	)

(1) There was no income tax on the loss from discontinued operations.

The following assets have been segregated and classified as assets held for sale in the consolidated balance sheet as of September 30, 2012 (in thousands):



	September 30,
	2012
Inventories	$	3,832
Prepaid expenses and other assets	1,369
Intangible assets, net	41,429
Goodwill	12,916
Assets held for sale	$	59,546

In October 2012, we completed the sale of the women's health business to Meda. See Note 16 Subsequent Event for more details.

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Income Tax

9 Months Ended

Sep. 30, 2012

Income Tax

Our provision for income taxes was $12.9 million and $25.0 million for the three and nine months ended September 30, 2012, respectively, compared to zero for the same periods in 2011. Our effective tax rate from continuing operations was 27.7% and 20.8% for the three and nine months ended September 30, 2012, respectively, compared to our effective tax rate of zero for the same periods in 2011. The provision for income taxes for the three and nine months ended September 30, 2012 was for taxes in foreign jurisdictions. During 2011, we had operations only in the U.S. and made no provision for income taxes due to our utilization of federal net operating loss carryforwards to offset both regular taxable income and alternative minimum taxable income and to our utilization of deferred state tax benefits. The 2012 effective tax rates were higher than the Irish statutory rate of 12.5% due to income taxable at a rate higher than the Irish statutory rate partially offset by a valuation allowance release in connection with the utilization of current year net operating losses.

We record a deferred tax asset or liability based on the difference between the financial statement and tax basis of our assets and liabilities, as measured by enacted jurisdictional tax rates assumed to be in effect when these differences reverse. Our deferred tax assets are composed primarily of U.S. federal net operating loss carryforwards and tax credit carryforwards. Based on available objective evidence, management believes it is more likely than not that these deferred tax assets are not recognizable and will not be recognizable until we have sufficient taxable income because of the risks and uncertainties described in Note 1. Accordingly, net deferred tax assets have been fully offset by a valuation allowance. We will continue to evaluate the need for a valuation allowance by jurisdiction on our deferred tax assets during each reporting period. If and when we reverse the valuation allowance, we will record a tax benefit in our consolidated statement of income. As of September 30, 2012, our deferred tax liability of $180.9 million primarily related to intangible assets and IPR&D acquired in the EUSA Acquisition.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Significant Risks and Uncertainties

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2012
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On October 15, 2012, we completed the sale of the women's health business to Meda for $97.6 million, including $2.6 million for certain inventory transferred to Meda upon the closing of the sale. Net proceeds of the sale are expected to be approximately $93 to $94 million. As part of the sale, approximately 60 employees who directly supported the women's health business became Meda employees. In the fourth quarter of 2012, we expect to record a non-recurring gain on the sale of approximately $34 to $36 million.

The Company and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Basis of Presentation

The consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.

Bus

Business Acquisitions

Concentrations of Risk

We rely on certain sole suppliers for drug substance and certain sole manufacturing partners for certain of our marketed products and product candidates.

Foreign Currency

Use of Estimates

Net Income per Ordinary Share



	Three Months Ended September 30,					Nine Months Ended September 30,
	2012			2011		2012			2011
Numerator:
Income from continuing operations	$	33,595		$	32,482	$	94,943		$	87,511
Loss from discontinued operations	(386		)	—		(6,908		)	—
Net income	$	33,209		$	32,482	$	88,035		$	87,511
Denominator:
Weighted-average ordinary shares - basic	57,703			42,028		56,198			41,206
Dilutive effect of employee equity incentive and purchase plans	1,404			2,632		1,557			2,773
Dilutive effect of warrants	1,776			2,581		2,091			2,598
Weighted-average ordinary shares - diluted	60,883			47,241		59,846			46,577

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.59		$	0.77	$	1.69		$	2.12
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.58		$	0.77	$	1.57		$	2.12
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.56		$	0.69	$	1.59		$	1.88
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.55		$	0.69	$	1.47		$	1.88



	Three Months Ended September 30,		Nine Months Ended September 30,
	2012	2011	2012	2011
Options to purchase ordinary shares and RSUs	1,785	1,335	1,314	1,122

Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2303973

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 05
-Paragraph 4
-Subparagraph (a)-(d)
-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 7
-Subparagraph a, b, c, d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-Section SEC Observer Comments
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 9, 10, 11, 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Disclosure of accounting policy for credit risk.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6487554&loc=d3e32600-158583

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14537-108613

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number SOP94-6-1
-Paragraph 7, 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 113
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 14
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 40
-Section 45
-URI http://asc.fasb.org/section&trid=2197723

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2197087

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33801-111570

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5, 6, 16-19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 96-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 20
-Subparagraph a(2)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 97-2
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph k
-Article 1

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 140
-Paragraph 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02, 03
-Article 3A

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

Basic and Diluted Net Income per Ordinary Share Computation

The Company and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2012			2011		2012			2011
Numerator:
Income from continuing operations	$	33,595		$	32,482	$	94,943		$	87,511
Loss from discontinued operations	(386		)	—		(6,908		)	—
Net income	$	33,209		$	32,482	$	88,035		$	87,511
Denominator:
Weighted-average ordinary shares - basic	57,703			42,028		56,198			41,206
Dilutive effect of employee equity incentive and purchase plans	1,404			2,632		1,557			2,773
Dilutive effect of warrants	1,776			2,581		2,091			2,598
Weighted-average ordinary shares - diluted	60,883			47,241		59,846			46,577

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.59		$	0.77	$	1.69		$	2.12
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.58		$	0.77	$	1.57		$	2.12
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.56		$	0.69	$	1.59		$	1.88
Loss from discontinued operations	(0.01		)	—		(0.12		)	—
Net income	$	0.55		$	0.69	$	1.47		$	1.88

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):



	Three Months Ended September 30,		Nine Months Ended September 30,
	2012	2011	2012	2011
Options to purchase ordinary shares and RSUs	1,785	1,335	1,314	1,122

Business Combinations (Tables)

9 Months Ended

Sep. 30, 2012

Unaudited Pro Forma Information

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations (in thousands, except per share data):



	Three Months Ended September 30,				Nine Months Ended September 30,

	2012		2011		2012		2011
Revenues	$	175,515	$	110,571	$	485,222	$	297,613
Net income (loss)	$	46,376	$	332	$	128,744	$	(12,353	)
Net income (loss) per ordinary share - basic	$	0.80	$	0.01	$	2.26	$	(0.23	)
Net income (loss) per ordinary share - diluted	$	0.76	$	0.01	$	2.12	$	(0.23	)

Assets Acquired and Liabilities Assumed at Acquisition Date Based upon Respective Estimated Fair Values



Cash and cash equivalents	$	81,751
Accounts receivable	12,975
Inventories	15,344
Property and equipment	370
Intangible assets	325,000
Goodwill	201,524
Other assets	4,862
Accounts payable and accrued liabilities	(52,148		)
Purchased product rights liability	(11,899		)
Above market lease obligation	(1,315		)
Total purchase price	$	576,464

Intangible Assets as of Closing Date of Acquisition

The intangible assets as of the closing date of the Azur Merger included (in thousands):



Acquired developed technologies	$	323,000
In-process research and development	2,000
Total intangible assets	$	325,000

Eusa Pharma

Assets Acquired and Liabilities Assumed at Acquisition Date Based upon Respective Estimated Fair Values



Cash and cash equivalents	$	54,117
Accounts receivable (1)	23,354
Inventories	36,360
Prepaid assets	6,212
Property and equipment	764
Intangible assets	616,970
Goodwill	206,452
Other assets	436
Accounts payable and accrued liabilities	(44,502		)
Deferred tax liability	(186,591		)
Other liabilities	(74		)
Total purchase price	$	713,498

Intangible Assets as of Closing Date of Acquisition

The intangible assets as of the closing date of the EUSA Acquisition included (in thousands):



Acquired developed technologies	$	584,470
In-process research and development	32,500
Total intangible assets	$	616,970

Summary of Cash Paid to Former Security Holders of EUSA Pharma

The initial estimate of fair value of the contingent consideration was $35.1 million, which was recorded as a non-current liability and included in the total purchase price as summarized below:



Base payment	$	650,000
Cash acquired	54,117
Working capital and other adjustments	(25,719		)
Upfront payment in accordance with agreement	678,398
Estimated fair value of contingent consideration	35,100
Total purchase price	$	713,498

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Components of Inventories

Inventories (Tables)

9 Months Ended

Sep. 30, 2012

The components of inventories were as follows (in thousands):



	September 30, 2012		December 31, 2011
Raw materials	$	5,888	$	1,937
Work in process	2,191		524
Finished goods	22,221		1,448
Total inventories	$	30,300	$	3,909

Fair Value (Tables)

9 Months Ended

Sep. 30, 2012

Cash Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities consisted of the following (in thousands):



	September 30, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	164,492	$	—	$	—		$	164,492	$	164,492	$	—
Money market funds	25,201		—		—			25,201		25,201		—
Certificates of deposit	100		—		—			100		100		—
Totals	$	189,793	$	—	$	—		$	189,793	$	189,793	$	—


	December 31, 2011
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	33,307	$	—	$	—		$	33,307	$	33,307	$	—
Money market funds	48,518		—		—			48,518		48,518		—
Certificates of deposit	7,300		—		(6		)	7,294		—		7,294
Corporate debt securities	50,371		7		(34		)	50,344		—		50,344
Obligations of U.S. government agencies	18,433		3		(1		)	18,435		251		18,184
Totals	$	157,929	$	10	$	(41	)	$	157,898	$	82,076	$	75,822

Available-for-Sale Securities and Other Assets and Liabilities Measured at Fair Value on Recurring Basis



	September 30, 2012								December 31, 2011
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value
Assets:
Available-for-sale securities
Money market funds	$	25,201	$	—	$	—	$	25,201	$	48,518	$	—	$	48,518
Certificates of deposit	—		100		—		100		—		7,294		7,294
Corporate debt securities	—		—		—		—		—		50,344		50,344
Obligations of U.S. government agencies	—		—		—		—		—		18,435		18,435
Total available-for-sale securities at fair value	$	25,201	$	100	$	—	$	25,301	$	48,518	$	76,073	$	124,591
Liabilities:
Contingent consideration	$	—	$	—	$	36,200	$	36,200	$	—	$	—	$	—

Roll forward of contingent consideration

The changes in fair value of the contingent consideration payable was estimated as follows (in thousands):



	Level 3
Balance at December 31, 2011	$	—
Amount acquired on June 12, 2012	35,100
Fair value adjustment recorded within selling, general and administrative expenses	1,100
Balance at September 30, 2012	$	36,200

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

Gross Carrying Amount of Goodwill

Certain Balance Sheet Items (Tables)

9 Months Ended

Sep. 30, 2012

Property and Equipment

Property and equipment consisted of the following (in thousands):



	September 30, 2012			December 31, 2011
Computer software	$	4,191		$	4,010
Computer equipment	3,163			2,046
Furniture and fixtures	1,729			556
Leasehold improvements	3,787			763
Construction-in-progress	1,052			689
Machinery and equipment	93			76
Subtotal	14,015			8,140
Less accumulated depreciation	(7,344		)	(6,583		)
Property and equipment, net	$	6,671		$	1,557

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):



	September 30, 2012		December 31, 2011
Employee compensation and benefits	$	24,761	$	11,643
Rebates and other sales deductions	27,178		12,378
Sales returns reserve	25,596		4,302
Taxes payable	25,449		—
Professional fees	3,217		4,021
Royalties	4,359		267
Other	13,072		2,172
Total accrued liabilities	$	123,632	$	34,783

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2012

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



Balance at December 31, 2011	$	38,213
Goodwill arising from the Azur Merger	201,524
Goodwill arising from the EUSA Acquisition	206,452
Goodwill allocated to the divested women's health business (1)	(12,916		)
Foreign exchange	4,379
Balance at September 30, 2012	$	437,652

_________________________


(1)	In September 2012, we entered into a definitive agreement to sell our women's health business. See Note 14 for information regarding discontinued operations and assets held for sale.

Gross Carrying Amounts and Net Book Values of Intangible Assets

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	September 30, 2012								December 31, 2011

	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	12.5	$	920,384	$	(79,265	)	$	841,119	$	49,400	$	(35,634	)	$	13,766
Trademarks	2.3	2,600		(1,985		)	615		2,600		(1,781		)	819
Total finite-lived intangible assets		922,984		(81,250		)	841,734		52,000		(37,415		)	14,585
Acquired IPR&D assets		35,225		—			35,225		—		—			—
Total intangible assets		$	958,209	$	(81,250	)	$	876,959	$	52,000	$	(37,415	)	$	14,585

Estimated Future Amortization Costs



Year Ending December 31,	Estimated Amortization Expense
2012 (remainder)	$	20,097
2013	77,208
2014	77,014
2015	70,077
2016	66,755
Thereafter	530,583
Total	$	841,734

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Future Minimum Lease Payments under Noncancelable Operating Leases

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2012

Future minimum lease payments under our noncancelable operating leases at September 30, 2012 were as follows (in thousands):



Year Ending December 31,	Lease Payments
2012 (remainder)	$	1,634
2013	6,800
2014	5,830
2015	5,032
2016	4,181
Thereafter	5,839
Total	$	29,316

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2012

Ordinary Shares Issued and Proceeds Received

The following table presents a summary of ordinary shares issued and related cash proceeds and payments (in thousands):



	Nine Months Ended September 30, 2012				Nine Months Ended September 30, 2011
	Shares	Cash			Shares	Cash
Azur Merger	12,360	$	—		—	$	—
Employee withholding taxes related to share option exercises (1)	—	(25,299		)	—	—
Employee stock purchase program, vesting of restricted stock units, option and warrant exercises	2,943	20,994			2,184	13,468
Directors deferred compensation plan	45	—			14	—
Totals	15,348	$	(4,305	)	2,198	$	13,468

____________________


(1)	During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees related to the net share settlement of exercised share options in connection with the Azur Merger.

Component of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive income (loss) as at September 30, 2012 and December 31, 2011 were as follows (in thousands):



	Net Unrealized Gains (Losses) On Available-For- Sale Securities			Foreign Currency Translation Adjustments		Total Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2011	$	(31	)	$	—	$	(31	)
Other comprehensive income, net of income taxes	31			13,860		13,891
Balance at September 30, 2012	$	—		$	13,860	$	13,860

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=14643745&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 150
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5

Share-Based Compensation Expense

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Selling, general and administrative	$	5,330	$	2,156	$	11,967	$	6,986
Research and development	681		838		1,718		2,342
Cost of product sales	344		201		999		430
Total share-based compensation expense	$	6,355	$	3,195	$	14,684	$	9,758

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share



	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Shares underlying options granted (in thousands)	1,157			61			2,077			1,312
Weighted-average grant date fair value	$	23.13		$	24.56		$	25.23		$	17.99
Black-Scholes option pricing model assumption information:
Weighted-average volatility	64		%	71		%	64		%	74		%
Weighted-average expected term (years)	4.2			5.6			4.6			5.6
Range of risk-free rates	0.5-0.6%			1.1-2.0%			0.5-1.1%			1.1-2.7%
Expected dividend yield	—		%	—		%	—		%	—		%

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

Summary of Total Revenues

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2012

The following table presents a summary of total revenues (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Xyrem	$	102,615	$	62,547	$	265,149	$	161,503
Erwinaze/Erwinase	31,652		—		37,660		—
Prialt	5,413		—		20,491		—
Psychiatry:
Luvox CR	11,605		9,669		31,634		24,080
FazaClo LD	6,370		—		17,905		—
FazaClo HD	3,057		—		8,979		—
Other	13,418		—		16,767		—
Product sales, net	174,130		72,216		398,585		185,583
Royalties and contract revenues	1,385		1,077		3,691		3,158
Total revenues	$	175,515	$	73,293	$	402,276	$	188,741

Summary of Total Revenues Attributed to Geographic Sources

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
United States	$	159,947	$	72,218	$	375,658	$	185,048
Europe	12,164		1,071		21,252		3,362
All other	3,404		4		5,366		331
Total revenues	$	175,515	$	73,293	$	402,276	$	188,741

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of total revenues from customers that represented more than 10% of our total revenues:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Express Scripts	58	%	85	%	66	%	85	%
Accredo Health Group, Inc.	14	%	—	%	7	%	—	%

Total Long-Lived Assets by Location

The following table presents total long-lived assets by location (in thousands):



	September 30, 2012		December 31, 2011
Ireland	$	191,012	$	—
France	722,877		—
Bermuda	251,887		—
United States	134,263		54,442
Other	41,648		—
Total long-lived assets	$	1,341,687	$	54,442

Restructuring (Tables)

9 Months Ended

Sep. 30, 2012

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs



	Total Termination Benefits
Balance at January 1, 2012	$	—
Costs incurred during the period	2,180
Cash payments	(1,367		)
Balance at September 30, 2012	$	813

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2012

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups

The following assets have been segregated and classified as assets held for sale in the consolidated balance sheet as of September 30, 2012 (in thousands):



	September 30,
	2012
Inventories	$	3,832
Prepaid expenses and other assets	1,369
Intangible assets, net	41,429
Goodwill	12,916
Assets held for sale	$	59,546

Net revenue and loss from discontinued operations are as follows (in thousands):



	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Product sales, net	$	8,086		$	19,277

Loss from discontinued operations (1)	$	(386	)	$	(6,908	)

(1) There was no income tax on the loss from discontinued operations.

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

Earnings Per Share Disclosure [Line Items]

The Company and Summary of Significant Accounting Policies - Additional Information (Detail) - Customer	Sep. 30, 2012	Dec. 31, 2011
Summary Of Significant Accounting Policies [Line Items]
Number of customers with significant accounts receivable	5
Percentage of gross accounts receivable	76.00%
Express Scripts
Summary Of Significant Accounting Policies [Line Items]
Number of customers with significant accounts receivable	1
Percentage of gross accounts receivable	50.00%	79.00%

Basic and Diluted Net Income (Loss) per Common Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

$ 33,595

$ 32,482

$ 94,943

$ 87,511

Weighted-average ordinary shares - basic

(386)

^[1]

(6,908)

^[1]

Net income

$ 33,209

$ 32,482

$ 88,035

$ 87,511

57,703

42,028

56,198

41,206

Dilutive effect of employee equity incentive and purchase plans

1,404

2,632

1,557

2,773

Dilutive effect of warrants

1,776

2,581

2,091

2,598

Weighted-average ordinary shares - diluted

60,883

47,241

59,846

46,577

Net income per ordinary share:

$ 0.59

$ 0.77

$ 1.69

$ 2.12

Net income (in dollars per basic share)

(0.01)

0.00

(0.12)

0.00

0.58

0.77

1.57

2.12

Net income per diluted share:

0.56

0.69

1.59

1.88

Net income (in dollars per diluted share)

(0.01)

0.00

(0.12)

0.00

$ 0.55

$ 0.69

$ 1.47

$ 1.88

[1]	There was no income tax on the loss from discontinued operations.

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options to purchase ordinary shares and RSUs	1,785	1,335	1,314	1,122

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Business Combinations - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jun. 12, 2012	Jan. 18, 2012	Jan. 17, 2012
Business Acquisition [Line Items]
Contingent consideration cash payment		$ 50,000		$ 50,000
Disposal Group, Including Discontinued Operation, Revenue		8,086		19,277
Minimum
Business Acquisition [Line Items]
Contingent consideration cash payment		0		0
Maximum
Business Acquisition [Line Items]
Contingent consideration cash payment		50,000		50,000
Acquired Finite Lived Intangible Assets Amortization
Business Acquisition [Line Items]
Pro forma adjustments		(1,300)	$ 15,700	8,900	$ 52,400
Transaction related expense
Business Acquisition [Line Items]
Pro forma adjustments			8,300	33,100	8,600
Finance charges
Business Acquisition [Line Items]
Pro forma adjustments		700		1,800
Interest expense
Business Acquisition [Line Items]
Pro forma adjustments			5,100		12,400
Fair value step up to acquired inventory
Business Acquisition [Line Items]
Pro forma adjustments		11,300	$ 9,400	58,400	$ 25,600
Azur Pharma
Business Acquisition [Line Items]
Total acquisition consideration							$ 576,464
Closing price, common stock								$ (46.64)
Ordinary shares outstanding							12,360,000
Ordinary shares ownership percentage							22.00%
Transaction costs				2,300
Business combination acquired entity contribution to total revenues		17,800		$ 51,800
Azur Pharma \| Maximum
Business Acquisition [Line Items]
Acquisition purchase price allocation finalization period after closing date				1 year
Azur Pharma \| Acquired developed technologies \| Minimum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets amortization period				2 years
Azur Pharma \| Acquired developed technologies \| Maximum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets amortization period				15 years
Jazz Pharmaceuticals Inc
Business Acquisition [Line Items]
Ordinary shares outstanding							43,838,000
Ordinary shares ownership percentage							78.00%
Eusa Pharma
Business Acquisition [Line Items]
Total acquisition consideration						$ 713,498
Transaction costs				$ 9,900
Business combination acquired entity contribution to total revenues		$ 42,100		$ 50,000
Upfront payment in accordance with agreement						678,398
Contingent consideration cash payment						50,000
Target sales						$ 124,500
Sales target completion Date						Dec. 31, 2013
Portion of purchase price placed in escrow	$ 47,700					$ 50,000
Escrow holding period						12 months
Contingent consideration payable subjected to reduction						$ 25,000
Fair value of contingent consideration liability						$ 35,100
Eusa Pharma \| Maximum
Business Acquisition [Line Items]
Acquisition purchase price allocation finalization period after closing date				1 year
Eusa Pharma \| Acquired developed technologies \| Minimum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets amortization period				2 years
Eusa Pharma \| Acquired developed technologies \| Maximum
Business Acquisition [Line Items]
Acquired finite-lived intangible assets amortization period				14 years
Subsequent Event \| Eusa Pharma
Business Acquisition [Line Items]
Business Aquisition, Working Capitial Adjustment	$ 2,300

Assets Acquired and Liabilities Assumed at Acquisition Date Based upon Respective Estimated Fair Values (Detail) - USD ($)
$ in Thousands

Jun. 12, 2012

Jan. 18, 2012

Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]

Cash and cash equivalents

$ 81,751

Accounts receivable

12,975

15,344

Property and equipment

370

Intangible assets

325,000

Accounts payable and accrued liabilities

201,524

Other assets

4,862

(52,148)

Purchased product rights liability

(11,899)

Above market lease obligation

(1,315)

Total purchase price

$ 576,464

Eusa Pharma

Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]

Cash and cash equivalents

$ 54,117

Accounts receivable

^[1]

23,354

36,360

Prepaid assets

6,212

Property and equipment

764

Intangible assets

616,970

Accounts payable and accrued liabilities

206,452

Other assets

436

(44,502)

Deferred tax liability

(186,591)

Other liabilities

(74)

Total purchase price

$ 713,498

[1]

Assets Acquired and Liabilities Assumed at Acquisition Date Based upon Respective Estimated Fair Values (Parenthetical) (Detail) - Eusa Pharma $ in Millions	Jun. 12, 2012 USD ($)
Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]
Estimated fair value of trade receivables acquired	$ 23.4
Gross contractual amount of trade receivables	25.1
Estimated uncollectible amount of trade receivable	$ 1.7

For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the best estimate at the acquisition date of the contractual cash flows not expected to be collected, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.

For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the fair value of the receivables acquired, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.

For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.

Intangible Assets as of Closing Date of Acquisition (Detail) - USD ($) $ in Thousands	Jun. 12, 2012	Jan. 18, 2012
Azur Pharma
Acquired Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Acquired developed technologies		$ 323,000
In-process research and development		2,000
Total intangible assets		$ 325,000
Eusa Pharma
Acquired Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Acquired developed technologies	$ 584,470
In-process research and development	32,500
Total intangible assets	$ 616,970

Summary of Cash Paid to Former Security Holders of EUSA Pharma (Detail) - Eusa Pharma $ in Thousands	Jun. 12, 2012 USD ($)
Business Acquisition [Line Items]
Base payment	$ 650,000
Cash acquired	54,117
Working capital and other adjustments	(25,719)
Upfront payment in accordance with agreement	678,398
Estimated fair value of contingent consideration	35,100
Total purchase price	$ 713,498

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4237-128469

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4243-128469

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Combined Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Business Acquisition, Pro Forma Information [Line Items]
Revenues	$ 175,515	$ 110,571	$ 485,222	$ 297,613
Net income (loss)	$ 46,376	$ 332	$ 128,744	$ (12,353)
Net income (loss) per ordinary share - basic	$ 0.80	$ 0.01	$ 2.26	$ (0.23)
Net income (loss) per ordinary share - diluted	$ 0.76	$ 0.01	$ 2.12	$ (0.23)

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Schedule of Inventory [Line Items]
Raw materials	$ 5,888	$ 1,937
Work in process	2,191	524
Finished goods	22,221	1,448
Total inventories	$ 30,300	$ 3,909

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Schedule of Inventory [Line Items]
Total inventories	$ 30,300	$ 3,909
Purchase accounting inventory fair value step up
Schedule of Inventory [Line Items]
Total inventories	$ 6,100

Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	$ 189,793	$ 157,929
Gross Unrealized Gains		10
Gross Unrealized Losses		(41)
Estimated Fair Value	189,793	157,898
Cash and cash equivalents	189,793	82,076	$ 101,215	$ 44,794
Marketable securities	0	75,822
Cash
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	164,492	33,307
Estimated Fair Value	164,492	33,307
Cash and cash equivalents	164,492	33,307
Money market funds
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	25,201	48,518
Estimated Fair Value	25,201	48,518
Cash and cash equivalents	25,201	48,518
Certificates of deposit
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	100	7,300
Gross Unrealized Losses		(6)
Estimated Fair Value	100	7,294
Cash and cash equivalents	$ 100
Marketable securities		7,294
Corporate debt securities
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost		50,371
Gross Unrealized Gains		7
Gross Unrealized Losses		(34)
Estimated Fair Value		50,344
Marketable securities		50,344
Obligations of U.S. government agencies
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost		18,433
Gross Unrealized Gains		3
Gross Unrealized Losses		(1)
Estimated Fair Value		18,435
Cash and cash equivalents		251
Marketable securities		$ 18,184

Fair Value - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Fair Value Measurements [Line Items]
Proceeds from sale of available-for-sale-securities	$ 81,246	$ 0
Fair value assets level 1 to level 2 transfers amount	0
Aggregate fair value of available-for-sale securities with unrealized losses			$ 43,600
Contingent consideration cash payment	50,000
Term Loans
Fair Value Measurements [Line Items]
Principal amount of term loan	475,000
Fair value of term loan	477,900
Carrying value of term loan	462,400
Minimum
Fair Value Measurements [Line Items]
Contingent consideration cash payment	0
Maximum
Fair Value Measurements [Line Items]
Contingent consideration cash payment	50,000
Erwinaze Target Sales \| Fair Value, Inputs, Level 3
Fair Value Measurements [Line Items]
Target sales	$ 124,500

Available-For-Sale Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	$ 189,793	$ 157,898
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	25,201	48,518
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	100	7,294
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		50,344
Obligations of U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		18,435
Fair Value, Measurements, Recurring
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	25,301	124,591
Contingent consideration	36,200
Fair Value, Measurements, Recurring \| Money market funds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	25,201	48,518
Fair Value, Measurements, Recurring \| Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	100	7,294
Fair Value, Measurements, Recurring \| Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		50,344
Fair Value, Measurements, Recurring \| Obligations of U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		18,435
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value, Measurements, Recurring
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	25,201	48,518
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value, Measurements, Recurring \| Money market funds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	25,201	48,518
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value, Measurements, Recurring \| Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	0
Fair Value, Inputs, Level 3 \| Fair Value, Measurements, Recurring
Schedule of Available-for-sale Securities [Line Items]
Contingent consideration	36,200
Significant Other Observable Inputs (Level 2) \| Fair Value, Measurements, Recurring
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	100	76,073
Significant Other Observable Inputs (Level 2) \| Fair Value, Measurements, Recurring \| Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis	$ 100	7,294
Significant Other Observable Inputs (Level 2) \| Fair Value, Measurements, Recurring \| Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		50,344
Significant Other Observable Inputs (Level 2) \| Fair Value, Measurements, Recurring \| Obligations of U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities measured at fair value on recurring basis		$ 18,435

Fair Value Level 3 Input Roll Forward (Details) - Contingent Consideration $ in Thousands	9 Months Ended
	Sep. 30, 2012 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0
Amounts acquired on June 12, 2012	35,100
Fair value adjustment included in operating expenses	1,100
Ending Balance	$ 36,200

Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Computer software	$ 4,191	$ 4,010
Computer equipment	3,163	2,046
Furniture and fixtures	1,729	556
Leasehold improvements	3,787	763
Construction-in-progress	1,052	689
Machinery and equipment	93	76
Subtotal	14,015	8,140
Less accumulated depreciation	(7,344)	(6,583)
Property and equipment, net	$ 6,671	$ 1,557

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Schedule of Accrued Liabilities [Line Items]
Employee compensation and benefits	$ 24,761	$ 11,643
Rebates and other sales deductions	27,178	12,378
Sales returns reserve	25,596	4,302
Taxes payable	25,449	0
Professional fees	3,217	4,021
Royalties	4,359	267
Other	13,072	2,172
Total accrued liabilities	$ 123,632	$ 34,783

Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Gross Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Goodwill [Line Items]
Goodwill	$ 437,652	$ 38,213

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Goodwill and Intangible Assets - Additional Information (Detail)
$ in Thousands

9 Months Ended

Sep. 30, 2012

USD ($)

Goodwill [Roll Forward]

Goodwill allocated to the divested women's health business (1)

$ 38,213

(12,916)

^[1]

Foreign exchange

4,379

437,652

Recorded goodwill in connection with the merger

Goodwill [Roll Forward]

201,524

Eusa Pharma

Goodwill [Roll Forward]

Recorded goodwill in connection with the merger

$ 206,452

[1]	In September 2012, we entered into a definitive agreement to sell our women's health business. See Note 14 for information regarding discontinued operations and assets held for sale.

Employee withholding tax paid related to net share option exercises

Gross Carrying Amounts and Net Book Values of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Intangible Assets, Net	$ 41,429
Gross Carrying Amount - Finite-Lived Intangible Assets	922,984	$ 52,000
Accumulated Amortization - Finite-Lived Intangible Assets	(81,250)	(37,415)
Net Book Value - Finite-Lived Intangible Assets	841,734	14,585
Gross Carrying Amount - Total Intangible Assets	958,209	52,000
Net Book Value - Total Intangible Assets	$ 876,959	14,585
Acquired developed technologies
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	12 years 6 months
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 920,384	49,400
Accumulated Amortization - Finite-Lived Intangible Assets	(79,265)	(35,634)
Net Book Value - Finite-Lived Intangible Assets	$ 841,119	13,766
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	2 years 3 months 18 days
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 2,600	2,600
Accumulated Amortization - Finite-Lived Intangible Assets	(1,985)	(1,781)
Net Book Value - Finite-Lived Intangible Assets	615	$ 819
Acquired IPR&D assets
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Acquired IPR&D assets - Indefinite-Lived Intangible Assets	$ 35,225

Estimated Future Amortization Costs (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Estimated Amortization Expense
2012 (remainder)	$ 20,097
2013	77,208
2014	77,014
2015	70,077
2016	66,755
Thereafter	530,583
Net Book Value - Finite-Lived Intangible Assets	$ 841,734	$ 14,585

Long-Term Debt - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 12, 2012	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 575,000
Principal repayments of term loan, quarterly payment			quarterly
Current portion of long-term debt		$ 26,719	$ 26,719	$ 0
First year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			5.00%
Second year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			7.50%
Third year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			10.00%
Fourth year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			10.00%
Fifth year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			15.00%
Sixth year
Line of Credit Facility [Line Items]
Percentage of repayment of principal Amount			15.00%
Credit Facility
Line of Credit Facility [Line Items]
Deferred finance costs	3,500
Increase to 75% if our secured leverage ratio exceeds 2.25 to 1.0 \| Maximum
Line of Credit Facility [Line Items]
Percentage of excess cash flow requirement		75.00%	75.00%
Secured leverage ratio		2.25	2.25
Decrease to 25% or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.0 or 0.75 to 1.0
Line of Credit Facility [Line Items]
Percentage of excess cash flow requirement		25.00%	25.00%
Decrease to 25% or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.0 or 0.75 to 1.0 \| Minimum
Line of Credit Facility [Line Items]
Percentage of excess cash flow requirement		0.00%	0.00%
Secured leverage ratio		0.75	0.75
Decrease to 25% or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.0 or 0.75 to 1.0 \| Maximum
Line of Credit Facility [Line Items]
Secured leverage ratio		1.25	1.25
Term Loans
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 475,000	$ 475,000	$ 475,000
Debt instrument term	6 years
Repayment premium percentage	1.00%
Mandatory prepayments from excess cash flows in 2013		50.00%	50.00%
Debt principle repaid		$ 5,900
Principal amount of term loan		$ 475,000	$ 475,000
Original issue debt discount	$ 7,100
Debt Issuance costs	$ 15,000
Interest rate of term loan		5.25%	5.25%
Effective interest rate of term loan		6.70%	6.70%
Current portion of long-term debt		$ 26,700	$ 26,700
Term Loans \| L I B O Rate
Line of Credit Facility [Line Items]
Applicable margin above base rate	4.25%
Debt instrument interest rate floor rate	1.00%
Term Loans \| Prime Rate
Line of Credit Facility [Line Items]
Applicable margin above base rate	3.25%
Debt instrument interest rate floor rate	2.00%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 100,000
Debt instrument term	5 years
Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Reduction in interest rate	0.25%
Commitment fee payable on undrawn amount	0.25%
Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Reduction in interest rate	0.50%
Commitment fee payable on undrawn amount	0.50%
Revolving Credit Facility \| L I B O Rate
Line of Credit Facility [Line Items]
Applicable margin above base rate	4.00%
Revolving Credit Facility \| Prime Rate
Line of Credit Facility [Line Items]
Applicable margin above base rate	3.00%
Swingline Subfacility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 10,000
Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 10,000

Future Minimum Lease Payments under Noncancelable Operating Leases (Detail) $ in Thousands	Sep. 30, 2012 USD ($)
Lease Payments
2012 (remainder)	$ 1,634
2013	6,800
2014	5,830
2015	5,032
2016	4,181
Thereafter	5,839
Total	$ 29,316

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended
	May 31, 2012	Oct. 18, 2012	Sep. 30, 2012	Jul. 10, 2012	Oct. 19, 2011
Commitments and Contingencies Disclosure [Line Items]
Noncancelable purchase commitments			$ 42.0
Lease Agreements \| Dublin
Commitments and Contingencies Disclosure [Line Items]
Operating lease term	10 years
Lease Agreements \| Philadelphia
Commitments and Contingencies Disclosure [Line Items]
Operating lease extended term	4 years
Lease Agreements \| Palo Alto
Commitments and Contingencies Disclosure [Line Items]
Operating sublease term	5 years
Minimum
Commitments and Contingencies Disclosure [Line Items]
Amounts sought in alleged breach of contractual obligation					$ 10.5
Maximum
Commitments and Contingencies Disclosure [Line Items]
Amounts sought in alleged breach of contractual obligation					$ 25.0
Roxane
Commitments and Contingencies Disclosure [Line Items]
Certification note		30 months
Xyrem
Commitments and Contingencies Disclosure [Line Items]
Certification note				30 months

Shareholders' Equity - Additional Information (Detail)	1 Months Ended
Shareholders' Equity - Additional Information (Detail)	Jan. 18, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jan. 18, 2012 € / shares	Jan. 18, 2012 USD ($) shares	Dec. 31, 2011 USD ($)
Stockholders Equity Note [Line Items]
Capital redemption reserve		$ 471,000		$ 500,000	$ 0
Ordinary Shares
Stockholders Equity Note [Line Items]
Increase in total par value of ordinary shares and deferred shares	$ 1,236
Euro Deferred Shares
Stockholders Equity Note [Line Items]
Increase in total par value of ordinary shares and deferred shares	54,862
Azur Pharma
Stockholders Equity Note [Line Items]
Total purchase price consideration				$ 576,464,000
Increase in additional paid-in capital	$ 575,900,000
Azur Pharma \| Euro Deferred Shares
Stockholders Equity Note [Line Items]
Outstanding non-voting euro deferred shares \| shares				4,000,000
Outstanding non-voting euro deferred shares, par value \| € / shares			€ 0.01

Ordinary Shares Issued and Proceeds Received (Detail) - USD ($)
shares in Thousands, $ in Thousands

9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Class of Stock [Line Items]

$ (25,299)

$ 0

Merger with Azur Pharma, shares issued

Class of Stock [Line Items]

12,360

Cash proceeds from merger

$ 0

Employee withholding tax paid related to net share option exercises

^[1]

Option and warrant exercises, shares issued

2,943

2,184

Directors deferred compensation plan, shares issued

Totals, shares issued

15,348

2,198

Employee withholding tax paid related to net share option exercises

^[1]

$ (25,299)

$ 0

Option and warrant exercises, cash proceeds

20,994

13,468

Directors deferred compensation plan

Totals, cash proceeds

$ (4,305)

$ 13,468

[1]	During the nine months ended September 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees related to the net share settlement of exercised share options in connection with the Azur Merger.

Ordinary Shares Issued and Proceeds Received (Parenthetical) (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Class of Stock [Line Items]
Employee withholding tax paid related to net share option exercises	$ 25,299	$ 0

Component of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2011			$ (31)
Other comprehensive income (loss)	$ 14,248	$ (2)	13,891	$ (2)
Balance at June 30, 2012	13,860		13,860
Net Unrealized Gains (Losses) On Available-For- Sale Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2011			(31)
Other comprehensive income (loss)			31
Balance at June 30, 2012	0		0
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2011			0
Other comprehensive income (loss)			13,860
Balance at June 30, 2012	$ 13,860		$ 13,860

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 6,355	$ 3,195	$ 14,684	$ 9,758
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	5,330	2,156	11,967	6,986
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	681	838	1,718	2,342
Cost of product sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	344	$ 201	999	$ 430
Share Options And Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense			$ 500
Discontinued operations \| Share Options And Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 300

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model Which Was Used to Estimate Grant Date Fair Value per Share (Detail) - Employee Stock Option - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Shares underlying options granted	1,157	61	2,077	1,312
Weighted-average grant date fair value	$ 23.13	$ 24.56	$ 25.23	$ 17.99
Weighted-average volatility	64.00%	71.00%	64.00%	74.00%
Weighted-average expected term (years)	4 years 2 months 16 days	5 years 7 months 6 days	4 years 7 months 6 days	5 years 7 months 6 days
Range of risk-free rates, minimum	0.50%	1.10%	0.50%	1.10%
Range of risk-free rates, maximum	0.60%	2.00%	1.10%	2.70%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Share-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2012 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock option and RSUs \| $	$ 80.7
Weighted-average period expected to be recognized	3 years 3 months 18 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares granted \| shares	1,000,000
Weighted average grant date fair value \| $ / shares	$ 48.98
Vesting period	4 years

Related Party Transactions - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Related Party Transaction [Line Items]
Number of shares sold in a secondary offering	7.9
Gross proceeds to selling shareholder	$ 390,700,000
Expenses in connection with secondary offering	$ 400,000
Related Party Mulligan
Related Party Transaction [Line Items]
Rentals payments		$ 200,000
Unpaid rent		$ 0
Related Party Circ
Related Party Transaction [Line Items]
Payment for license			$ 250,000
Agreement termination date		2012-07

Segment Reporting - Additional Information (Detail)	9 Months Ended
Segment Reporting - Additional Information (Detail)	Sep. 30, 2012 Segment
Segment Reporting Disclosure [Line Items]
Number of operating business segment	1

Summary of Total Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Summary of Total Revenues (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue from External Customer [Line Items]
Product sales, net	$ 174,130	$ 72,216	$ 398,585	$ 185,583
Royalties and contract revenues	1,385	1,077	3,691	3,158
Total revenues	175,515	73,293	402,276	188,741
Xyrem
Revenue from External Customer [Line Items]
Product sales, net	102,615	62,547	265,149	161,503
Erwinaze And Erwinase
Revenue from External Customer [Line Items]
Product sales, net	31,652		37,660
Prialt
Revenue from External Customer [Line Items]
Product sales, net	5,413		20,491
Luvox CR
Revenue from External Customer [Line Items]
Product sales, net	11,605	$ 9,669	31,634	$ 24,080
Faza Clo Ld
Revenue from External Customer [Line Items]
Product sales, net	6,370		17,905
Faza Clo Hd
Revenue from External Customer [Line Items]
Product sales, net	3,057		8,979
Other
Revenue from External Customer [Line Items]
Product sales, net	$ 13,418		$ 16,767

Summary of Total Revenues Attributed to Geographic Sources (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 175,515	$ 73,293	$ 402,276	$ 188,741
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	159,947	72,218	375,658	185,048
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	12,164	1,071	21,252	3,362
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 3,404	$ 4	$ 5,366	$ 331

Summary of Revenues from Customers Representing at Least 10% of Total Revenues (Detail) - Sales Revenue, Goods, Net	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Express Scripts
Revenue, Major Customer [Line Items]
Percentage of total revenues	58.00%	85.00%	66.00%	85.00%
Accredo Health Group, Inc.
Revenue, Major Customer [Line Items]
Percentage of total revenues	14.00%	0.00%	7.00%	0.00%

Total Long-Lived Assets by Location (Detail) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	$ 1,341,687	$ 54,442
IRELAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	191,012
France
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	722,877
Bermuda
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	251,887
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	134,263	$ 54,442
Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived assets	$ 41,648

Restructuring Restructuring (Details) $ in Thousands	3 Months Ended	9 Months Ended
Restructuring Restructuring (Details) $ in Thousands	Sep. 30, 2012 USD ($)	Sep. 30, 2012 USD ($)
Restructuring Cost and Reserve [Line Items]
Amount expected to be charged against earnings in future periods for the specified restructuring cost	$ 1,000	$ 1,000
One-time Termination Benefits
Restructuring Reserve [Roll Forward]
Balance		0
Cash payments		(1,367)
Balance	813	813
Selling, general and administrative \| One-time Termination Benefits
Restructuring Reserve [Roll Forward]
Costs incurred during the period	$ 1,600	$ 2,180

Discontinued Operations (Details)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2012

USD ($)

Sep. 30, 2011

USD ($)

Sep. 30, 2012

USD ($)

Sep. 30, 2011

USD ($)

Sep. 05, 2012

USD ($)

employee

product

Dec. 31, 2011

USD ($)

The sales price of the discontinued operation excluding inventory

$ 95,000

Number of products sold | product

The number of employees offered positions by purchaser of the discontinued operation | employee

Revenue and Loss from operations for discontinued operations

Product sales, net

$ 8,086

$ 19,277

(386)

^[1]

$ 0

(6,908)

^[1]

$ 0

ASSETS

Prepaid expenses and other assets

3,832

1,369

Intangible assets, net

41,429